科兴制药：GB18注射液I期临床试验完成首例受试者入组

Core Viewpoint - The announcement indicates that the Phase I clinical trial for "GB18 Injection," developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Pharmaceutical, has successfully completed the enrollment and administration of the first subject [1] Group 1 - The clinical trial is a significant milestone for the company, showcasing its progress in drug development [1] - "GB18 Injection" is part of the company's ongoing efforts to expand its product pipeline and enhance its market position [1]